<DOC>
	<DOCNO>NCT00680953</DOCNO>
	<brief_summary>Evaluate efficacy safety denosumab treatment involutional ( postmenopausal senile ) osteoporotic subject prevalent fragility vertebral fracture ( )</brief_summary>
	<brief_title>Denosumab Fracture Intervention Randomized Placebo Controlled Trial Japanese Patients With Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>Involutional ( postmenopausal senile ) osteoporosis prevalent fragility vertebral fracture Any underlying condition , ( BMD ) might result abnormal bone metabolism</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>